Myeloma Center

You are here

News

Changing the Cancer Conversation
In the June issue of Delta Sky Magazine, Dr. Ruben Niesvizky weighs in on the latest progress in multiple myeloma treatment.
2016 American Society for Clinical Oncology (ASCO) Presentation
In myeloma, there are numerous choices for therapy. We recommend treatments based on the risk level of the disease. Patients are divided into two groups, standard risk and high risk. In most centers, risk categorization is an important consideration when deciding the best course of treatment. Assessing risk typically involves the underlying health and age of the patient, the extent of disease, and genetic abnormalities within the cells. The standard system to classify extent or "stage" is...
Myeloma Center Awarded Prestigious LLS Translational Research Grant
The Myeloma Center in collaboration with Weill Cornell's Monical Guzman, PhD have received a prestigious translational research grant from the Leukemia and Lymphoma Society (LLS) to study the genesis of secondary malignancies in Multiple Myeloma.Multiple Myeloma is characterized by the uncontrolled proliferation of malignant plasma cells. The introduction of novel agents has resulted in improvement in survival. However, long term use of these agents may lead to the development of second primary...

Weill Cornell Medicine Myeloma Center 425 East 61st St
8th Floor
New York, NY 10065 Phone: (646) 962-6500 Fax: (212) 746-8961